KYMCO
16.11.2023 11:27:28 CET | Business Wire | Press release
Building on the pinnacle of over 25 years of EV innovation, KYMCO announced three ground-breaking technologies to accelerate the mass-adoption of electric motorcycles: The Ionex Battery-as-a-Service Solution for Energy Companies, the Ionex Battery Metering Unit for EV Manufacturers, and the Ionex Energy Station for Battery-swapping Network Operators. "Today, we stand on the brink of a remarkable transformation in the world of mobility. A shift that reshapes the way we move, a change that KYMCO leads," said Allen Ko, Chairman of KYMCO.
KYMCO's Vision: A World with Electric Motorcycles Everywhere
KYMCO sees Energy Companies provide riders with battery services for electric motorcycles. With this battery service, the riders receive batteries from energy companies with guaranteed performance and pay only for actual battery usage. Riders no longer need to buy batteries when purchasing their vehicle.
KYMCO sees EV Manufacturers introduce electric motorcycles with integrated onboard battery metering. Every electric motorcycle works with the Energy Companies' battery service. Without the costs of the batteries, electric motorcycles are more affordable than ever before.
KYMCO sees Battery-swapping Network Operators deploying thousands of battery-swapping stations, forever erasing range anxiety. Battery-swapping networks provide riders with zero-wait charging and unlimited range.
More profoundly, KYMCO sees riders choosing from a wide variety of electric motorcycles made by various manufacturers and battery service plans that best match their lifestyles. For energy replenishment, riders charge their vehicle in the garage or charge their battery in the house. In the city, riders swap on the go at the nearest battery-swapping station. And while traveling, riders get unlimited range from the extensive battery-swapping network to power all their journeys.
Ionex EV Solution: The True Arrival of the Electric Era
To address all current challenges and future ambitions to fulfill KYMCO's vision, Chairman Ko announced three ground-breaking technologies to propel all stakeholders to collaborate as the Ionex Open Consortium, an EV ecosystem that brings affordable, convenient, and sustainable electric mobility to all, the true arrival of the electric era.
The Ionex Battery-as-a-Service Solution for Energy Companies, the Ionex Battery Metering Unit for EV Manufacturers, and the Ionex Energy Station for Battery-swapping Network Operators make up the revolutionary Ionex EV Solution. The Ionex EV Solution aims to benefit every stakeholder in electric mobility, especially all consumers, businesses, and governments wishing to go electric.
"We look forward to seeing the impact the Ionex EV Solution will have on Southeast Asia's fast-developing EV ecosystem. We see its potential to bring about more affordable and convenient electric mobility," expressed Chuck Kim, Managing Director of Group Business Development and Capital Markets, Grab.
"Right here, right now, marks the inflection point of the electric era," said Allen Ko. "KYMCO's game-changing Ionex EV Solution is paving the way for all stakeholders to jointly transition to the electric future. I invite everyone to join us on this transformative journey."
About KYMCO
KYMCO is a brand with a rich history spanning nearly 60 years in the powersport industry. They focus on innovation, quality, style and have established themselves as a leading manufacturer of scooters, motorcycles, and ATVs worldwide. Their state-of-the-art manufacturing facilities and use of the latest technologies ensure that every vehicle they produce is reliable and stylish.
KYMCO is committed to reducing the environmental footprint, promoting sustainability, supporting social causes, and giving back to the communities. Whether riders seek a sleek and sporty scooter or a rugged and durable ATV, KYMCO has something for everyone. KYMCO is a brand that embodies the best of what the powersport industry offers - innovation, quality, style, and a commitment to making the world a better place.
You can learn more about KYMCO at www.kymco.com
Learn more about Ionex at www.ionexenergy.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231115883583/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom